Core Viewpoint - Jiangsu Kangyuan Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for clinical trials of Jinzhen Oral Liquid for the treatment of children's influenza, indicating a significant step in expanding its market potential [1][2]. Group 1: Drug Development and Market Situation - Jinzhen Oral Liquid is a proprietary traditional Chinese medicine for children, composed of eight herbal ingredients, and has been included in the National Essential Medicines List and the National Medical Insurance Directory [2]. - The new indication for Jinzhen Oral Liquid targets children's influenza, a respiratory infectious disease caused by the influenza virus, with studies showing its efficacy in reducing viral load and improving lung health [2][3]. - The annual infection rate of influenza among children under five in China is reported to be as high as 20%-30%, with certain peak seasons reaching around 50%, highlighting the significant market opportunity for Jinzhen Oral Liquid [3]. Group 2: Financial Performance and Future Steps - The projected revenue for Jinzhen Oral Liquid in 2024 is approximately 81.52 million yuan [4]. - Following the receipt of the clinical trial approval, the company must complete Phase II and III clinical trials and submit the registration application for the drug [4].
江苏康缘药业股份有限公司关于 金振口服液增加适应症获得临床试验批准通知书的公告